Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

Tailoring cells for clinical needs: Meeting report from the Advanced Therapy in Healthcare symposium (October 28-29 2017, Doha, Qatar).

Deola S, Guerrouahen BS, Sidahmed H, Al-Mohannadi A, Elnaggar M, Elsadig R, Abdelalim EM, Petrovski G, Gadina M, Thrasher A, Wels WS, Hunger SP, Wang E, Marincola FM; ATH Consortium, Maccalli C, Cugno C.

J Transl Med. 2018 Oct 10;16(1):276. doi: 10.1186/s12967-018-1652-y.

2.

The role of cancer stem cells in the modulation of anti-tumor immune responses.

Maccalli C, Rasul KI, Elawad M, Ferrone S.

Semin Cancer Biol. 2018 Dec;53:189-200. doi: 10.1016/j.semcancer.2018.09.006. Epub 2018 Sep 24. Review.

PMID:
30261276
3.

Immune Profiling of Cancer Patients Treated with Immunotherapy: Advances and Challenges.

Pilla L, Maccalli C.

Biomedicines. 2018 Jul 2;6(3). pii: E76. doi: 10.3390/biomedicines6030076. Review.

4.

Methods for improving the immunogenicity and efficacy of cancer vaccines.

Pilla L, Ferrone S, Maccalli C.

Expert Opin Biol Ther. 2018 Jul;18(7):765-784. doi: 10.1080/14712598.2018.1485649. Epub 2018 Jun 17. Review.

PMID:
29874943
5.

A collection of annotated and harmonized human breast cancer transcriptome datasets, including immunologic classification.

Roelands J, Decock J, Boughorbel S, Rinchai D, Maccalli C, Ceccarelli M, Black M, Print C, Chou J, Presnell S, Quinn C, Jithesh P, Syed N, Al Bader SBJ, Bedri S, Wang E, Marincola FM, Chaussabel D, Kuppen P, Miller LD, Bedognetti D, Hendrickx W.

Version 2. F1000Res. 2017 Mar 20 [revised 2018 Jan 1];6:296. doi: 10.12688/f1000research.10960.2. eCollection 2017.

6.

Immunogenomic Classification of Colorectal Cancer and Therapeutic Implications.

Roelands J, Kuppen PJK, Vermeulen L, Maccalli C, Decock J, Wang E, Marincola FM, Bedognetti D, Hendrickx W.

Int J Mol Sci. 2017 Oct 24;18(10). pii: E2229. doi: 10.3390/ijms18102229. Review.

7.

Soluble NKG2D ligands are biomarkers associated with the clinical outcome to immune checkpoint blockade therapy of metastatic melanoma patients.

Maccalli C, Giannarelli D, Chiarucci C, Cutaia O, Giacobini G, Hendrickx W, Amato G, Annesi D, Bedognetti D, Altomonte M, Danielli R, Calabrò L, Di Giacomo AM, Marincola FM, Parmiani G, Maio M.

Oncoimmunology. 2017 May 8;6(7):e1323618. doi: 10.1080/2162402X.2017.1323618. eCollection 2017.

8.

Immunotherapy biomarkers 2016: overcoming the barriers.

Gulley JL, Berzofsky JA, Butler MO, Cesano A, Fox BA, Gnjatic S, Janetzki S, Kalavar S, Karanikas V, Khleif SN, Kirsch I, Lee PP, Maccalli C, Maecker H, Schlom J, Seliger B, Siebert J, Stroncek DF, Thurin M, Yuan J, Butterfield LH.

J Immunother Cancer. 2017 Mar 21;5(1):29. doi: 10.1186/s40425-017-0225-6.

9.

Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis.

Hendrickx W, Simeone I, Anjum S, Mokrab Y, Bertucci F, Finetti P, Curigliano G, Seliger B, Cerulo L, Tomei S, Delogu LG, Maccalli C, Wang E, Miller LD, Marincola FM, Ceccarelli M, Bedognetti D.

Oncoimmunology. 2017 Feb 6;6(2):e1253654. doi: 10.1080/2162402X.2016.1253654. eCollection 2017.

10.

Immunomodulating and Immunoresistance Properties of Cancer-Initiating Cells: Implications for the Clinical Success of Immunotherapy.

Maccalli C, Parmiani G, Ferrone S.

Immunol Invest. 2017 Apr;46(3):221-238. doi: 10.1080/08820139.2017.1280051. Epub 2017 Mar 13. Review.

PMID:
28287848
11.

"Cancer Bio-Immunotherapy in Siena": Thirteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 8-10, 2015.

Maio M, Bertocci E, Fazio C, Chiarucci C, Cutaia O, Scala E, Giacobini G, Lofiego MF, Fonsatti E, Maccalli C, Nicolay HJ, Parmiani G; NIBIT.

Cancer Immunol Immunother. 2016 Nov;65(11):1423-1431. Epub 2016 Sep 12. No abstract available.

PMID:
27619513
12.

Checkpoint Inhibitors and Their Application in Breast Cancer.

Bedognetti D, Maccalli C, Bader SB, Marincola FM, Seliger B.

Breast Care (Basel). 2016 Apr;11(2):108-15. doi: 10.1159/000445335. Epub 2016 Apr 26. Review.

13.

Harnessing the immune system for the treatment of melanoma: current status and future prospects.

Guennoun A, Sidahmed H, Maccalli C, Seliger B, Marincola FM, Bedognetti D.

Expert Rev Clin Immunol. 2016 Aug;12(8):879-93. doi: 10.1080/1744666X.2016.1176529. Epub 2016 May 3. Review.

PMID:
27070898
14.

Immunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus fotemustine in the NIBIT-M1 study.

Maccalli C, Giannarelli D, Capocefalo F, Pilla L, Fonsatti E, Di Giacomo AM, Parmiani G, Maio M.

Oncoimmunology. 2015 Aug 12;5(2):e1071007. eCollection 2016 Feb.

15.

Novel technologies and emerging biomarkers for personalized cancer immunotherapy.

Yuan J, Hegde PS, Clynes R, Foukas PG, Harari A, Kleen TO, Kvistborg P, Maccalli C, Maecker HT, Page DB, Robins H, Song W, Stack EC, Wang E, Whiteside TL, Zhao Y, Zwierzina H, Butterfield LH, Fox BA.

J Immunother Cancer. 2016 Jan 19;4:3. doi: 10.1186/s40425-016-0107-3. eCollection 2016. Review.

16.

T cell neoepitope discovery in colorectal cancer by high throughput profiling of somatic mutations in expressed genes.

Mennonna D, Maccalli C, Romano MC, Garavaglia C, Capocefalo F, Bordoni R, Severgnini M, De Bellis G, Sidney J, Sette A, Gori A, Longhi R, Braga M, Ghirardelli L, Baldari L, Orsenigo E, Albarello L, Zino E, Fleischhauer K, Mazzola G, Ferrero N, Amoroso A, Casorati G, Parmiani G, Dellabona P.

Gut. 2017 Mar;66(3):454-463. doi: 10.1136/gutjnl-2015-309453. Epub 2015 Dec 17.

17.

Integrating Immune Checkpoint Blockade with Anti-Neo/Mutated Antigens Reactivity to Increase the Clinical Outcome of Immunotherapy.

Parmiani G, Maccalli C, Maio M.

Vaccines (Basel). 2015 May 21;3(2):420-8. doi: 10.3390/vaccines3020420. Review.

18.

"Cancer Bio-Immunotherapy in Siena": Twelfth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 9-11, 2014.

Maio M, Bertocci E, Pilla L, Fazio C, Chiarucci C, Cutaia O, Fonsatti E, Maccalli C, Parmiani G; NIBIT.

Cancer Immunol Immunother. 2016 Jan;65(1):119-26. doi: 10.1007/s00262-015-1699-z. Epub 2015 May 6. No abstract available.

PMID:
25944004
19.

A pilot Phase I study combining peptide-based vaccination and NGR-hTNF vessel targeting therapy in metastatic melanoma.

Parmiani G, Pilla L, Corti A, Doglioni C, Cimminiello C, Bellone M, Parolini D, Russo V, Capocefalo F, Maccalli C.

Oncoimmunology. 2014 Dec 21;3(11):e963406. eCollection 2014 Nov.

20.

Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study.

Di Giacomo AM, Ascierto PA, Queirolo P, Pilla L, Ridolfi R, Santinami M, Testori A, Simeone E, Guidoboni M, Maurichi A, Orgiano L, Spadola G, Del Vecchio M, Danielli R, Calabrò L, Annesi D, Giannarelli D, Maccalli C, Fonsatti E, Parmiani G, Maio M.

Ann Oncol. 2015 Apr;26(4):798-803. doi: 10.1093/annonc/mdu577. Epub 2014 Dec 23.

PMID:
25538176
21.

Peptide-based vaccines for cancer therapy.

Parmiani G, Russo V, Maccalli C, Parolini D, Rizzo N, Maio M.

Hum Vaccin Immunother. 2014;10(11):3175-8. doi: 10.4161/hv.29418. Review.

22.

Somatically mutated tumor antigens in the quest for a more efficacious patient-oriented immunotherapy of cancer.

Trajanoski Z, Maccalli C, Mennonna D, Casorati G, Parmiani G, Dellabona P.

Cancer Immunol Immunother. 2015 Jan;64(1):99-104. doi: 10.1007/s00262-014-1599-7. Epub 2014 Aug 28. Review.

PMID:
25164877
23.

Cancer stem cells: perspectives for therapeutic targeting.

Maccalli C, De Maria R.

Cancer Immunol Immunother. 2015 Jan;64(1):91-7. doi: 10.1007/s00262-014-1592-1. Epub 2014 Aug 8. Review.

PMID:
25104304
24.

Immunology of cancer stem cells in solid tumours. A review.

Maccalli C, Volontè A, Cimminiello C, Parmiani G.

Eur J Cancer. 2014 Feb;50(3):649-55. doi: 10.1016/j.ejca.2013.11.014. Epub 2013 Dec 12. Review.

PMID:
24333096
25.

Cancer-initiating cells from colorectal cancer patients escape from T cell-mediated immunosurveillance in vitro through membrane-bound IL-4.

Volonté A, Di Tomaso T, Spinelli M, Todaro M, Sanvito F, Albarello L, Bissolati M, Ghirardelli L, Orsenigo E, Ferrone S, Doglioni C, Stassi G, Dellabona P, Staudacher C, Parmiani G, Maccalli C.

J Immunol. 2014 Jan 1;192(1):523-32. doi: 10.4049/jimmunol.1301342. Epub 2013 Nov 25.

26.

Increasing immunogenicity of cancer vaccines to improve their clinical outcome.

Parmiani G, Cimminiello C, Maccalli C.

Expert Rev Vaccines. 2013 Oct;12(10):1111-3. doi: 10.1586/14760584.2013.839274. No abstract available.

PMID:
24124873
27.

Human NK cells selective targeting of colon cancer-initiating cells: a role for natural cytotoxicity receptors and MHC class I molecules.

Tallerico R, Todaro M, Di Franco S, Maccalli C, Garofalo C, Sottile R, Palmieri C, Tirinato L, Pangigadde PN, La Rocca R, Mandelboim O, Stassi G, Di Fabrizio E, Parmiani G, Moretta A, Dieli F, Kärre K, Carbone E.

J Immunol. 2013 Mar 1;190(5):2381-90. doi: 10.4049/jimmunol.1201542. Epub 2013 Jan 23.

29.

Ex vivo enrichment of circulating anti-tumor T cells from both cutaneous and ocular melanoma patients: clinical implications for adoptive cell transfer therapy.

Mazzarella T, Cambiaghi V, Rizzo N, Pilla L, Parolini D, Orsenigo E, Colucci A, Modorati G, Doglioni C, Parmiani G, Maccalli C.

Cancer Immunol Immunother. 2012 Aug;61(8):1169-82. doi: 10.1007/s00262-011-1179-z. Epub 2011 Dec 30.

30.

Defining the critical hurdles in cancer immunotherapy.

Fox BA, Schendel DJ, Butterfield LH, Aamdal S, Allison JP, Ascierto PA, Atkins MB, Bartunkova J, Bergmann L, Berinstein N, Bonorino CC, Borden E, Bramson JL, Britten CM, Cao X, Carson WE, Chang AE, Characiejus D, Choudhury AR, Coukos G, de Gruijl T, Dillman RO, Dolstra H, Dranoff G, Durrant LG, Finke JH, Galon J, Gollob JA, Gouttefangeas C, Grizzi F, Guida M, Håkansson L, Hege K, Herberman RB, Hodi FS, Hoos A, Huber C, Hwu P, Imai K, Jaffee EM, Janetzki S, June CH, Kalinski P, Kaufman HL, Kawakami K, Kawakami Y, Keilholtz U, Khleif SN, Kiessling R, Kotlan B, Kroemer G, Lapointe R, Levitsky HI, Lotze MT, Maccalli C, Maio M, Marschner JP, Mastrangelo MJ, Masucci G, Melero I, Melief C, Murphy WJ, Nelson B, Nicolini A, Nishimura MI, Odunsi K, Ohashi PS, O'Donnell-Tormey J, Old LJ, Ottensmeier C, Papamichail M, Parmiani G, Pawelec G, Proietti E, Qin S, Rees R, Ribas A, Ridolfi R, Ritter G, Rivoltini L, Romero PJ, Salem ML, Scheper RJ, Seliger B, Sharma P, Shiku H, Singh-Jasuja H, Song W, Straten PT, Tahara H, Tian Z, van Der Burg SH, von Hoegen P, Wang E, Welters MJ, Winter H, Withington T, Wolchok JD, Xiao W, Zitvogel L, Zwierzina H, Marincola FM, Gajewski TF, Wigginton JM, Disis ML.

J Transl Med. 2011 Dec 14;9:214. doi: 10.1186/1479-5876-9-214.

31.

Autologous versus allogeneic cell-based vaccines?

Parmiani G, Pilla L, Maccalli C, Russo V.

Cancer J. 2011 Sep-Oct;17(5):331-6. doi: 10.1097/PPO.0b013e3182337a76. Review.

PMID:
21952283
32.

Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers.

Butterfield LH, Palucka AK, Britten CM, Dhodapkar MV, Håkansson L, Janetzki S, Kawakami Y, Kleen TO, Lee PP, Maccalli C, Maecker HT, Maino VC, Maio M, Malyguine A, Masucci G, Pawelec G, Potter DM, Rivoltini L, Salazar LG, Schendel DJ, Slingluff CL Jr, Song W, Stroncek DF, Tahara H, Thurin M, Trinchieri G, van Der Burg SH, Whiteside TL, Wigginton JM, Marincola F, Khleif S, Fox BA, Disis ML.

Clin Cancer Res. 2011 May 15;17(10):3064-76. doi: 10.1158/1078-0432.CCR-10-2234. Epub 2011 May 10. Review.

33.

Immunobiological characterization of cancer stem cells isolated from glioblastoma patients.

Di Tomaso T, Mazzoleni S, Wang E, Sovena G, Clavenna D, Franzin A, Mortini P, Ferrone S, Doglioni C, Marincola FM, Galli R, Parmiani G, Maccalli C.

Clin Cancer Res. 2010 Feb 1;16(3):800-13. doi: 10.1158/1078-0432.CCR-09-2730. Epub 2010 Jan 26.

34.

A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers".

Butterfield LH, Disis ML, Fox BA, Lee PP, Khleif SN, Thurin M, Trinchieri G, Wang E, Wigginton J, Chaussabel D, Coukos G, Dhodapkar M, Håkansson L, Janetzki S, Kleen TO, Kirkwood JM, Maccalli C, Maecker H, Maio M, Malyguine A, Masucci G, Palucka AK, Potter DM, Ribas A, Rivoltini L, Schendel D, Seliger B, Selvan S, Slingluff CL Jr, Stroncek DF, Streicher H, Wu X, Zeskind B, Zhao Y, Zocca MB, Zwierzina H, Marincola FM.

J Transl Med. 2008 Dec 23;6:81. doi: 10.1186/1479-5876-6-81.

35.

TNK cells (NKG2D+ CD8+ or CD4+ T lymphocytes) in the control of human tumors.

Maccalli C, Scaramuzza S, Parmiani G.

Cancer Immunol Immunother. 2009 May;58(5):801-8. doi: 10.1007/s00262-008-0635-x. Epub 2008 Dec 17. Review.

PMID:
19089424
36.

Induction of both CD8+ and CD4+ T-cell-mediated responses in colorectal cancer patients by colon antigen-1.

Maccalli C, Di Cristanziano V, Fodale V, Corsi D, D'Agostino G, Petrangeli V, Laurenti L, Guida S, Mazzocchi A, Arienti F, Perrone MP, Castelli C, Rivoltini L, Zagonel V, Tartaglia M, Parmiani G, Belardelli F.

Clin Cancer Res. 2008 Nov 15;14(22):7292-303. doi: 10.1158/1078-0432.CCR-08-0832. Epub 2008 Oct 30.

37.

NKG2D-mediated antitumor activity by tumor-infiltrating lymphocytes and antigen-specific T-cell clones isolated from melanoma patients.

Maccalli C, Nonaka D, Piris A, Pende D, Rivoltini L, Castelli C, Parmiani G.

Clin Cancer Res. 2007 Dec 15;13(24):7459-68.

38.

Universal and stemness-related tumor antigens: potential use in cancer immunotherapy.

Parmiani G, Russo V, Marrari A, Cutolo G, Casati C, Pilla L, Maccalli C, Rivoltini L, Castelli C.

Clin Cancer Res. 2007 Oct 1;13(19):5675-9. No abstract available.

39.

Natural killer and NK-Like T-cell activation in colorectal carcinoma patients treated with autologous tumor-derived heat shock protein 96.

Pilla L, Squarcina P, Coppa J, Mazzaferro V, Huber V, Pende D, Maccalli C, Sovena G, Mariani L, Castelli C, Parmiani G, Rivoltini L.

Cancer Res. 2005 May 1;65(9):3942-9.

40.

Identification of a colorectal tumor-associated antigen (COA-1) recognized by CD4(+) T lymphocytes.

Maccalli C, Li YF, El-Gamil M, Rosenberg SA, Robbins PF.

Cancer Res. 2003 Oct 15;63(20):6735-43.

41.

NKG2D engagement of colorectal cancer-specific T cells strengthens TCR-mediated antigen stimulation and elicits TCR independent anti-tumor activity.

Maccalli C, Pende D, Castelli C, Mingari MC, Robbins PF, Parmiani G.

Eur J Immunol. 2003 Jul;33(7):2033-43.

42.

Immunology and immunotherapy of colorectal cancer.

Dalerba P, Maccalli C, Casati C, Castelli C, Parmiani G.

Crit Rev Oncol Hematol. 2003 Apr;46(1):33-57. Review.

PMID:
12672517
43.

Differential loss of T cell signaling molecules in metastatic melanoma patients' T lymphocyte subsets expressing distinct TCR variable regions.

Maccalli C, Pisarra P, Vegetti C, Sensi M, Parmiani G, Anichini A.

J Immunol. 1999 Dec 15;163(12):6912-23.

44.

Intralesional selection of T cell clonotypes in the immune response to melanoma antigens occurring during vaccination.

Sensi M, Farina C, Maccalli C, Anichini A, Berd D, Parmiani G.

J Immunother. 1998 May;21(3):198-204.

PMID:
9610911
45.
46.

Clonal expansion of T lymphocytes in human melanoma metastases after treatment with a hapten-modified autologous tumor vaccine.

Sensi M, Farina C, Maccalli C, Lupetti R, Nicolini G, Anichini A, Parmiani G, Berd D.

J Clin Invest. 1997 Feb 15;99(4):710-7.

47.

Cytotoxic T cells directed to tumor antigens not expressed on normal melanocytes dominate HLA-A2.1-restricted immune repertoire to melanoma.

Anichini A, Mortarini R, Maccalli C, Squarcina P, Fleischhauer K, Mascheroni L, Parmiani G.

J Immunol. 1996 Jan 1;156(1):208-17.

PMID:
8598464
48.

A human melanoma cell line transduced with an interleukin-4 gene by a retroviral vector releases biologically active IL-4 and maintains the original tumor antigenic phenotype.

Melani C, Sulé-Suso J, Arienti F, MacCalli C, Passerini F, Colombo MP, Parmiani G.

Hum Gene Ther. 1995 Nov;6(11):1427-36.

PMID:
8573615
49.

Cytotoxic T-lymphocyte clones from different patients display limited T-cell-receptor variable-region gene usage in HLA-A2-restricted recognition of the melanoma antigen Melan-A/MART-1.

Sensi M, Traversari C, Radrizzani M, Salvi S, Maccalli C, Mortarini R, Rivoltini L, Farina C, Nicolini G, Wölfel T, et al.

Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5674-8.

50.

Interleukin-2 gene-transduced human melanoma cells efficiently stimulate MHC-unrestricted and MHC-restricted autologous lymphocytes.

Arienti F, Sulé-Suso J, Melani C, Maccalli C, Belli F, Illeni MT, Anichini A, Cascinelli N, Colombo MP, Parmiani G.

Hum Gene Ther. 1994 Sep;5(9):1139-50.

PMID:
7833372

Supplemental Content

Loading ...
Support Center